Novo Nordisk Company - Search News

The Motley Fool · 1h

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Business Insider · 19h

Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price

Investing.com on MSN · 21h

BofA reiterates Buy on Novo Nordisk shares on performance

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting a significant downturn in the second half of 2024,

TipRanks on MSN · 22h

Novo Nordisk price target lowered to $110 from $140 at Argus

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the stock’s

Business Insider · 22h

Argus Research Remains a Buy on Novo Nordisk (NVO)

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The

21hon MSN

Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...

19hon MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

19h

LVMH overtakes Novo Nordisk as Europe’s most valuable company

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...

20hon MSN

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

2d

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

1d

Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

FiercePharma23h

Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

11d

Drug Company to Share Revenues With Indigenous People Who Donated Their Genes

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

9d

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs

Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...

3d

Novo Nordisk: Excellent Opportunity To Buy The Dip

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results